Abzena Supplies Clinical Trial Material for Angiex’s AGX101 Study

09 August 2024

Abzena Supplies Clinical Trial Material for Angiex’s AGX101 Study

Angiex’s Phase I clinical trial for AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC), is progressing with the support of clinical trial materials supplied by Abzena. This groundbreaking therapy focuses on targeting the blood vessels that feed aggressive tumors, making it a novel approach in oncology. The partnership between Angiex and Abzena ensures that AGX101 has the necessary resources to continue advancing through its early clinical stages.

Pipeline Review featured this development, highlighting the role Abzena plays in enabling cutting-edge clinical trials. The publication brings attention to how collaborations like this are critical for driving forward innovations in cancer treatment. As AGX101 moves ahead in clinical testing, the partnership showcases how biopharmaceutical companies can work together to accelerate progress in oncology.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch